Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.
Axel WesterYing ShangEmilie Toresson GripAnthony A MatthewsHannes HagströmPublished in: Gut (2024)
In patients with chronic liver disease and type 2 diabetes who adhered to therapy over time, GLP1 agonists may result in lower risk of MALO. This suggests that GLP1 agonists are promising agents to reduce risk of chronic liver disease progression in patients with concurrent type 2 diabetes, although this needs to be corroborated in randomised trials.
Keyphrases
- type diabetes
- glycemic control
- cardiovascular disease
- clinical trial
- insulin resistance
- open label
- emergency department
- randomized controlled trial
- double blind
- study protocol
- metabolic syndrome
- adipose tissue
- radiation therapy
- mesenchymal stem cells
- squamous cell carcinoma
- weight loss
- bone marrow
- placebo controlled
- locally advanced
- rectal cancer
- adverse drug